The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Cemiplimab efficacy by PD-L1 expression in the EMPOWER-Lung 1 trial of NSCLC
The Phase III EMPOWER-Lung 1 trial (NCT03088540) investigated the efficacy of cemiplimab, an anti-PD-1 monoclonal antibody, compared to platinum doublet chemotherapy in patients with non-small cell lung cancer (NSCLC) and PD-L1 expression levels above 50%. Saadettin Kiliçkap, MD, Hacettepe University Cancer Institute, Ankara, Turkey, discusses an exploratory analysis of the EMPOWER-Lung 1 trial, assessing the clinical significance of PD-L1 expression levels in a randomized sub-population. The study found that cemiplimab treatment resulted in significantly better overall survival, progression-free survival and overall response rates compared to treatment with chemotherapy. Additionally, incremental benefits were seen with increasing PD-L1 expression in the cemiplimab arm but not the chemotherapy arm. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
